Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy.
Department of Ophthalmology, Humanitas Gradenigo, Corso Regina Margherita 8/10, 10153 Torino, Italy.
Eur J Ophthalmol. 2024 May;34(3):NP18-NP21. doi: 10.1177/11206721241228005. Epub 2024 Jan 22.
We report a series of 5 cases, happened in a period of 5 months, who developed neurotrophic keratopathy (NK) following pars plana vitrectomy (PPV) and retinal endolaser for rhegmatogenous retinal detachment (RRD). In our several decennary experience of surgical center predominantly based on vitreoretinal surgery, we had rare cases of postoperative NK. These recent cases of post-surgical NK happened contextually to our change of postoperative non-steroidal anti-inflammatory drugs (NSAIDs) drops, based on Ketorolac Tromethamine 0.5% eye drops.
Five patients with a mean age of 61 ± 7.3 years were treated with one or more PPV with intraoperative peripheral endolaser for RRD. Nobody had previous herpetic keratitis, systemic disease like diabetes mellitus or other predisposing factors for NK. In the postoperative period, all patients received Ketorolac Tromethamine 0.5% eye drops for a mean period of 54 ± 25 days. During follow-up visits they developed NK and they were successfully treated with suspension of Ketorolac eye drops, application of therapeutic contact lens or amniotic membrane patch and topical lubricant therapy.
Postoperative Ketorolac eye drops, in patients who underwent PPV with endolaser, may reduce the corneal sensitivity, predispose to epithelial disruption and NK development. Studies are needed to explore the effect of NSAIDs on corneal sensitivity reduction in patient who will undergo PPV and extensive endolaser.
我们报告了 5 例连续病例,这些病例均发生在 5 个月内,他们在接受巩膜平坦部玻璃体切除术(PPV)和视网膜内激光光凝治疗孔源性视网膜脱离(RRD)后发生神经营养性角膜病变(NK)。在我们以玻璃体视网膜手术为主的手术中心,我们拥有数十年的经验,很少发生术后 NK。最近这几例术后 NK 病例与我们术后非甾体抗炎药(NSAIDs)滴剂的变化有关,我们基于酮咯酸氨丁三醇 0.5%滴眼剂进行了更改。
5 名患者的平均年龄为 61±7.3 岁,他们接受了 1 次或多次 PPV 治疗,并在术中进行了周边视网膜内激光光凝治疗 RRD。没有人有疱疹性角膜炎病史、糖尿病等系统性疾病或其他导致 NK 的易感因素。在术后期间,所有患者均接受酮咯酸氨丁三醇 0.5%滴眼剂治疗,平均持续 54±25 天。在随访过程中,他们出现了 NK,并通过停止使用酮咯酸滴眼剂、应用治疗性隐形眼镜或羊膜贴片以及局部润滑剂治疗成功治疗。
接受 PPV 和内激光光凝治疗的患者术后使用酮咯酸滴眼剂可能会降低角膜敏感性,导致上皮破裂和 NK 发展。需要进行研究以探讨 NSAIDs 对接受 PPV 和广泛内激光光凝治疗的患者角膜敏感性降低的影响。